Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:LYEL NASDAQ:OGI NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$10.95-0.1%$9.51$5.01▼$18.70$65.26M0.2665,116 shs25,038 shsLYELLyell Immunopharma$10.98-3.0%$10.26$7.65▼$32.40$169.72M-0.1969,530 shs34,694 shsOGIOrganigram Global$1.45+2.5%$1.40$0.85▼$2.08$193.67M1.45534,663 shs601,169 shsSCPHscPharmaceuticals$4.63-7.6%$4.46$1.94▼$6.28$246.78M0.4338,919 shs846,492 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics0.00%-5.19%+18.63%+69.24%+44.46%LYELLyell Immunopharma0.00%-0.36%+12.62%+30.22%-64.12%OGIOrganigram Global0.00%+8.65%-0.34%+12.89%-1.70%SCPHscPharmaceuticals0.00%-10.44%+5.71%+86.69%+6.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.7207 of 5 stars3.41.00.04.70.03.30.6LYELLyell Immunopharma3.2946 of 5 stars2.85.00.00.00.03.31.3OGIOrganigram Global0.7262 of 5 stars0.02.00.00.00.60.02.5SCPHscPharmaceuticals3.7166 of 5 stars3.52.00.04.20.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.83Moderate Buy$20.0082.65% UpsideLYELLyell Immunopharma 1.50Reduce$15.0036.61% UpsideOGIOrganigram Global 0.00N/AN/AN/ASCPHscPharmaceuticals 3.00Buy$14.00202.38% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, OGI, LYEL, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.51N/AN/A($16.89) per share-0.65LYELLyell Immunopharma$60K2,829.18N/AN/A$26.21 per share0.42OGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70SCPHscPharmaceuticals$36.33M6.79N/AN/A$0.27 per share17.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/13/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1014.45N/AN/A8.05%-5.93%-4.39%8/13/2025 (Confirmed)SCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%N/ALatest ATRA, OGI, LYEL, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LYELLyell Immunopharma-$0.19N/AN/AN/AN/AN/A8/13/2025Q3 2025OGIOrganigram Global-$0.01N/AN/AN/A$68.04 millionN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32N/AN/AN/A$4.23 millionN/A8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 million5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57LYELLyell ImmunopharmaN/A7.497.49OGIOrganigram GlobalN/A3.421.90SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%LYELLyell Immunopharma66.05%OGIOrganigram Global34.63%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%LYELLyell Immunopharma22.30%OGIOrganigram Global0.09%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableLYELLyell Immunopharma27015.46 million12.01 millionOptionableOGIOrganigram Global860134.03 million133.91 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableATRA, OGI, LYEL, and SCPH HeadlinesRecent News About These CompaniesWall Street Zen Upgrades scPharmaceuticals (NASDAQ:SCPH) to "Hold"August 10 at 3:32 AM | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)August 9 at 4:23 PM | theglobeandmail.comscPharmaceuticals (NASDAQ:SCPH) Upgraded to Hold at Wall Street ZenAugust 9 at 3:37 AM | americanbankingnews.comSCPH Revenue Up 99%August 9 at 2:24 AM | aol.comAScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025August 9 at 2:24 AM | msn.comscPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call TranscriptAugust 8 at 3:03 PM | seekingalpha.comscPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue EstimatesAugust 7, 2025 | zacks.comscPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comShareholders in scPharmaceuticals (NASDAQ:SCPH) are in the red if they invested five years agoAugust 5, 2025 | uk.finance.yahoo.comscPharmaceuticals (SCPH) to Release Earnings on ThursdayAugust 5, 2025 | marketbeat.comscPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025July 31, 2025 | globenewswire.comscPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?July 25, 2025 | zacks.comscPharmaceuticals, Inc. (NASDAQ:SCPH) Shares Sold by AIGH Capital Management LLCJuly 22, 2025 | marketbeat.comRice Hall James & Associates LLC Boosts Stock Position in scPharmaceuticals, Inc. (NASDAQ:SCPH)July 14, 2025 | marketbeat.comWith 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interestJune 12, 2025 | finance.yahoo.comscPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025May 22, 2025 | seekingalpha.comscPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 16, 2025 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Lucid’s 36% Rally on Uber Deal Could Be a Game-ChangerBy Leo Miller | July 22, 2025View Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer4 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q23 Cloud Build-Out Stocks Behind the AI Infrastructure BoomBy Chris Markoch | July 25, 2025View 3 Cloud Build-Out Stocks Behind the AI Infrastructure BoomWhat's Behind Opendoor Technologies' Rally? Is Meme Mania Back?By Gabriel Osorio-Mazilli | July 23, 2025View What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?Why Prologis May Be the Smartest Backdoor Bet on AI Real EstateBy Chris Markoch | July 17, 2025View Why Prologis May Be the Smartest Backdoor Bet on AI Real EstateATRA, OGI, LYEL, and SCPH Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$10.95 -0.01 (-0.09%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.91 +0.96 (+8.78%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Lyell Immunopharma NASDAQ:LYEL$10.98 -0.34 (-3.00%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.02 +0.04 (+0.36%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Organigram Global NASDAQ:OGI$1.44 +0.04 (+2.48%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$1.50 +0.05 (+3.81%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.scPharmaceuticals NASDAQ:SCPH$4.63 -0.38 (-7.58%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.65 +0.02 (+0.45%) As of 08/8/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale